Alan J. Arville, Member of the Firm in the Health Care & Life Sciences practice, in the firm’s Washington, DC, office, was quoted in the 340B Report, in “340B Provider Camp Cheers HHS Letter to Lilly, Pharma Camp Says the Fight Isn’t Over,” by Tom Mirga.
Following is an excerpt:
Groups and attorneys representing 340B covered entities yesterday applauded the U.S. Health and Human Services Department (HHS) for rebuking drug manufacturer Eli Lilly and Co. over the company’s decision to end practically all 340B pricing on its products dispensed by 340B contract pharmacies. The groups say they will keep fighting in federal agencies, Congress, and possibly the courts to stop Lilly and other companies that follow Lilly’s lead. …
Here is how groups and attorneys reacted to HHS’s letter to Lilly:
Alan Arville, Member, Epstein Becker Green
The practical effect of HHS’s letter may be that other drug manufacturers pause and wait for HRSA’s response before implementing a policy similar to Eli Lilly’s.